返回 
加入收藏
艾迪注射液辅助奥沙利铂联合替吉奥治疗晚期结直肠癌的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 艾迪注射液辅助奥沙利铂联合替吉奥治疗晚期结直肠癌的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察艾迪注射液辅助奥沙利铂联合替吉奥治疗晚期结直肠癌的疗效和安全性。方法：100例晚期结直肠癌患者随机均分为对照组和观察组。对照组患者给予替吉奥胶囊，体表面积＜1.25 m2，40 mg，体表面积≥1.25～＜1.50 m2，50 mg，＞1.50 m2，60 mg，早晚餐后口服，d1～28，后停药14 d+奥沙利铂85～130 mg/m2加入5％葡萄糖注射液500 ml中，静脉滴注2 h，d1；观察组患者在对照组治疗的基础上加用艾迪注射液100 ml加入5％葡萄糖注射液500 ml，静脉滴注，每日1次，d1～7，间隔14 d重复1次，共2次。观察两组患者的临床疗效，毒性反应，生存质量改善情况和1年生存率。结果：两组患者总有效率比较，差异无统计学意义（P＞0.05）。观察组患者生存质量提高率、1年生存率均显著高于对照组，粒细胞减少、血小板下降、口腔溃疡、外周神经毒性总发生率均显著低于对照组，差异均有统计学意义（P＜0.05）。结论：艾迪注射液辅助奥沙利铂联合替吉奥治疗晚期结直肠癌较奥沙利铂联合替吉奥的生存质量和1年生存率均较高，且安全性更好。 |
| ABSTRACT： | OBJECTIVE： To observe the efficacy and safety of Aidi injection combined with oxaliplatin and tegafur gimeracil oteracil potassium in the treatment of advanced colorectal cancer. METHODS：100 patients with advanced colorectal cancer were randomly divided into control group and observation group. Control group was treated with Tegafur gimeracil oteracil potassium capsule，body surface area＜1.25 m2，40 mg； while body surface area ≥1.25-＜1.50 m2，50 mg and ＞1.50 m2，60 mg，it was orally taken after breakfast and dinner d1-28，the drug was stopped for 14 d after 28 d treatment+oxaliplatin 85-130 mg/m2 adding into 500 ml of 5％ Glucose injection by intravenous infusion for 2 h. Observation group was additionally treated with Aidi injection 100 ml adding into 500 ml of 5％ Glucose injection by intravenous infusion， once a day， d1-7， which was repeated every 14 d and was twice. The clinical efficacy， toxicity reactions， improvement of life quality and one-year survival rates in the two groups were observed. RESULTS： There was no statistically significant difference in the total effective rate between 2 groups （P＞0.05）. The improvement rate of life quality and one-year survival rate in the observation group were significantly higher than control group， the incidence rates of granulocytopenia， platelet decline， oral ulcer and peripheral neurotoxicity in observation group were significantly lower than control group， there was significant difference between 2 groups （P＜0.05）. CONCLUSIONS： The life qnality and one-year surviral rate of Aidi injection combined with oxaliplatin and tegafur gimeracil oteracil potassium is better than only oxaliplatin combined with tegafur gimeracil oteracil potassium in the treatment of advanced colorectal cancer， with better safety. |
| 期刊： | 2015年第26卷第36期 |
| 作者： | 张仕林 |
| AUTHORS： | ZHANG Shi-lin |
| 关键字： | 晚期结直肠癌；艾迪注射液；奥沙利铂；替吉奥；疗效；安全性 |
| KEYWORDS： | Advanced colorectal cancer； Aioli injection； Oxaliplatin； Tegafur gimeracil oteracil potassium； Efficacy； Safety |
| 阅读数： | 255 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
